ArticleFrontiers in endocrinology2025
Discordance of diabetic retinopathy severity in a cohort of diabetic nephropathy patients: a cross-sectional case-control study in a new Mexican population of type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although diabetic retinopathy (DR) and diabetic nephropathy (DN) are well known microvascular complications of diabetes, the correlation between DR and DN remains uncertain. Several studies have suggested differences in etiology and risk factors between these two complications. Objectives: To examine whether diabetic retinopathy (DR) and nephropathy (DN) have significant concordance in terms of severity progression in patients with type 2 diabetes. Methods: A case-control study was conducted involving two cohorts of type 2 diabetic patients from a New Mexican population. The cases had confirmed end-stage renal disease (ESRD; Stage 5, on dialysis, Results: The majority (65%) of the ESRD cohort had proliferative diabetic retinopathy (PDR), while 18% of patients exhibited no diabetic retinopathy (DR) or mild non-proliferative diabetic retinopathy (NPDR). Conversely, approximately 38% of the mild DN cohort had PDR. In the univariate analysis, ESRD was significantly associated with lower HbA1c levels (p<0.0001) and higher systolic blood pressure (p<0.0001). Within the ESRD cohort, the onset of PDR was significantly linked to younger age (p=0.0002), higher diastolic blood pressure (p=0.0319), and elevated LDL (p=0.0361). In the multivariate analysis, the development of PDR was inversely related to age (p=0.001, OR=0.95) and positively correlated with serum creatinine (p<0.0001, OR=1.25), systolic blood pressure (p=0.0221, OR=1.023), and albuminuria (p=0.0006, OR=4.65). HbA1c levels showed no significant correlation with the progression of PDR. The use of PDR as a screening tool for chronic kidney disease (CKD) has a sensitivity of 78.68% and a specificity of 51.16%, indicating that it is a suboptimal screening method. Conclusions: Our findings suggest discordance between the progression of diabetic retinopathy and nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.